Swedish Orphan Biovitrum Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Guido Oelkers

İcra Kurulu Başkanı

SEK 55.5m

Toplam tazminat

CEO maaş yüzdesi	24.5%
CEO görev süresi	8yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	5.3yrs
Yönetim Kurulu ortalama görev süresi	4.5yrs

Son yönetim güncellemeleri

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next

May 02

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Price In Tune With Earnings

Apr 18

Does Swedish Orphan Biovitrum (STO:SOBI) Deserve A Spot On Your Watchlist?

Feb 28

Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 07

Swedish Orphan Biovitrum (STO:SOBI) Has A Pretty Healthy Balance Sheet

Jan 21

Earnings Tell The Story For Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Dec 30

Innovative Product Launches And Global Expansion Drive Bright Future In Sobi's Portfolio

Nov 20 Expansion of hematology and immunology divisions, with new product launches, drives strong revenue growth and market positioning.

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24

CEO Tazminat Analizi

Guido Oelkers'un ücretlendirmesi Swedish Orphan Biovitrum'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2025	n/a	n/a	SEK 4b
Dec 31 2024	SEK 56m	SEK 14m	SEK 4b
Sep 30 2024	n/a	n/a	SEK 4b
Jun 30 2024	n/a	n/a	SEK 2b
Mar 31 2024	n/a	n/a	SEK 2b
Dec 31 2023	SEK 49m	SEK 12m	SEK 2b
Sep 30 2023	n/a	n/a	SEK 3b
Jun 30 2023	n/a	n/a	SEK 3b
Mar 31 2023	n/a	n/a	SEK 3b
Dec 31 2022	SEK 47m	SEK 11m	SEK 3b
Sep 30 2022	n/a	n/a	SEK 2b
Jun 30 2022	n/a	n/a	SEK 3b
Mar 31 2022	n/a	n/a	SEK 3b
Dec 31 2021	SEK 42m	SEK 10m	SEK 3b
Sep 30 2021	n/a	n/a	SEK 3b
Jun 30 2021	n/a	n/a	SEK 3b
Mar 31 2021	n/a	n/a	SEK 3b
Dec 31 2020	SEK 33m	SEK 10m	SEK 3b
Sep 30 2020	n/a	n/a	SEK 3b
Jun 30 2020	n/a	n/a	SEK 3b
Mar 31 2020	n/a	n/a	SEK 4b
Dec 31 2019	SEK 33m	SEK 10m	SEK 3b
Sep 30 2019	n/a	n/a	SEK 3b
Jun 30 2019	n/a	n/a	SEK 3b
Mar 31 2019	n/a	n/a	SEK 3b
Dec 31 2018	SEK 26m	SEK 9m	SEK 2b

Tazminat ve Piyasa: Guido 'nin toplam tazminatı ($USD 5.75M ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.85M ).

Tazminat ve Kazançlar: Guido 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Guido Oelkers (59 yo)

8yrs

Görev süresi

SEK 55,533,000

Tazminat

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Guido Oelkers	CEO & President	8yrs	SEK 55.53m	0.15% SEK 157.6m
Henrik Stenqvist	Chief Financial Officer	6.8yrs	Veri yok	0.023% SEK 23.5m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	6.3yrs	Veri yok	0.015% SEK 15.0m
Daniel Rankin	Head of Strategy & Corporate Development	3.3yrs	Veri yok	0.0025% SEK 2.5m
Lena Bjurner	Head of Human Resources	2.3yrs	Veri yok	Veri yok
Norbert Oppitz	Head of International	7.6yrs	Veri yok	0.018% SEK 18.5m
Sofiane Fahmy	Head of Europe	6.3yrs	Veri yok	0.014% SEK 14.0m
Duane Barnes	Head of North America	4.3yrs	Veri yok	0.0050% SEK 5.1m
Mahmood Ladha	Head of Strategic Transformation Operations	no data	Veri yok	0.0055% SEK 5.6m
Christine Wesstrom	Head of Technical Operations	3.2yrs	Veri yok	0.0054% SEK 5.5m
Lydia Abad-Franch	Senior VP	2.3yrs	Veri yok	0.0018% SEK 1.8m

5.3yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: SOBI 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hans Wigzell	Chairman of Scientific Advisory Board	24.3yrs	SEK 158.00k	Veri yok
Helena Saxon	Director	14.1yrs	SEK 101.00k	0.0066% SEK 6.8m
Anders Ullman	Director	2yrs	SEK 648.00k	0.0010% SEK 1.0m
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ralf Pettersson	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stefan Del Prato	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Annette Clancy	Independent Director	11yrs	SEK 2.21m	0.00099% SEK 1.0m
Staffan Schuberg	Independent Director	5yrs	SEK 907.00k	0.0021% SEK 2.1m
Filippa Stenberg	Director	4yrs	SEK 733.00k	0.00017% SEK 173.5k
David Meek	Independent Chairman	less than a year	SEK 175.00k	Veri yok
Katy Mazibuko	Employee Representative Director	2.3yrs	Veri yok	0.0013% SEK 1.3m

4.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SOBI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/07 15:10
Gün Sonu Hisse Fiyatı	2025/05/07 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Swedish Orphan Biovitrum AB (publ) 30 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
null null	ABG Sundal Collier
Xue Chen	Barclays
Rosie Turner	Barclays

Swedish Orphan Biovitrum Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Swedish Orphan Biovitrum AB (Publ) Appoints Iris Loew-Friedrich as Board Member

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 08, 2025

Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

CEO & President recently sold kr29m worth of stock

Recent updates

Swedish Orphan Biovitrum AB (Publ) Appoints Iris Loew-Friedrich as Board Member

Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2025 Results on Feb 05, 2026

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Price In Tune With Earnings

Full year 2024 earnings: EPS exceeds analyst expectations

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 08, 2025

Sobi Announces Research Collaboration Involving New Phase 2a Clinical Trial for Gamifant

Does Swedish Orphan Biovitrum (STO:SOBI) Deserve A Spot On Your Watchlist?

US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg)

Apellis Pharmaceuticals, Inc. and Sobi Announces EMA Validation of Indication Extension Application for Aspaveli®? (Pegcetacoplan) for C3g and Primary Ic-Mpgn

Consensus EPS estimates fall by 13%

Swedish Orphan Biovitrum AB (publ) Just Recorded A 8.0% EPS Beat: Here's What Analysts Are Forecasting Next

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2025

Full year 2024 earnings: EPS exceeds analyst expectations

Swedish Orphan Biovitrum (STO:SOBI) Has A Pretty Healthy Balance Sheet

Earnings Tell The Story For Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors

Innovative Product Launches And Global Expansion Drive Bright Future In Sobi's Portfolio

Price target increased by 8.2% to kr357

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

General Counsel & Head of Legal Affairs recently sold kr27m worth of stock

Investor sentiment improves as stock rises 15%

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

CEO & President recently sold kr29m worth of stock

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 21%

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Head of North America recently sold kr37m worth of stock

CEO & President recently sold kr30m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

New minor risk - Shareholder dilution

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.